The Imaging Core has been introduced, thanks to a supplementary grant awarded by NCI in 1998. The idea of including imaging expertise to this Program rose through the scientific interaction of Program investigators with Dr. Blasberg and Dr. Tjuvajev; some of which have already generated joint publications The main objective of the core will be to support eh individual projects with respect to monitoring the distribution of genetically engineered cells in vivo, in pre-clinical and eventually in clinical studies. For instance, the homing of genetically altered T cells to tumor sites can be monitored by quantitative, non-invasive imaging using positron emission tomography (PET) or gamma camera imaging techniques.
The aims of the core will be pursued be building on published studies, which have demonstrated the ability to selectively image HSV1- tk transgene expression. The rationale for the proposed imaging experiments is based on preliminary data showing that T cells expressing HSV1-tk can be sequentially imaged and monitored as they migrate through the body to the target (tumor) site. The potential of the Imaging Core is based on the scientific expertise of its leader Dr. Ronald Blasberg and of the other investigators, who have strong rack records in the area of in vitro and in vivo imaging. The Imaging Core has access to highly sophisticated instruments, which taken together, constitute a unique set of imaging apparatus in terms of achieving a resolution power suitable for the analysis of relatively small numbers of cells in small animals. The Imaging Core will facilitate Project 1, Project 2 and Project 4 to image and monitor targeting of genetically altered T cells to tumors. With Project 3, the Imaging Core will image and monitor in vivo homing of hematopoietic cells to bone marrow. If these imaging goals can be achieved in experimental animals, it is expected that they will be directly transferable to human studies using currently available clinical imaging facilities at MSKCC, including positron emission tomography (PET) and magnetic resonance imaging (MRI).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA059350-08
Application #
6401815
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1992-09-30
Project End
2005-04-30
Budget Start
Budget End
Support Year
8
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Smith, Eric L; Staehr, Mette; Masakayan, Reed et al. (2018) Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector. Mol Ther 26:1447-1456
Budhu, Sadna; Schaer, David A; Li, Yongbiao et al. (2017) Blockade of surface-bound TGF-? on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci Signal 10:
Yeku, Oladapo; Li, Xinghuo; Brentjens, Renier J (2017) Adoptive T-Cell Therapy for Solid Tumors. Am Soc Clin Oncol Educ Book 37:193-204
Daniyan, Anthony F; Brentjens, Renier J (2017) Immunotherapy: Hiding in plain sight: immune escape in the era of targeted T-cell-based immunotherapies. Nat Rev Clin Oncol 14:333-334
Sadelain, Michel; Rivière, Isabelle; Riddell, Stanley (2017) Therapeutic T cell engineering. Nature 545:423-431
Yeku, Oladapo O; Brentjens, Renier J (2016) Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans 44:412-8
Batlevi, Connie Lee; Matsuki, Eri; Brentjens, Renier J et al. (2016) Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol 13:25-40
Jackson, Hollie J; Rafiq, Sarwish; Brentjens, Renier J (2016) Driving CAR T-cells forward. Nat Rev Clin Oncol 13:370-83
Boice, Michael; Salloum, Darin; Mourcin, Frederic et al. (2016) Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell 167:405-418.e13

Showing the most recent 10 out of 186 publications